New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation

NCT ID NCT07628062

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a new treatment plan for people with HPV-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The plan combines an immune-boosting drug (nogapendekin alfa inbakicept), a vaccine targeting HPV, chemotherapy, and a lower dose of radiation. The goal is to see if this approach is safe and works better than the standard treatment, while possibly reducing long-term side effects from radiation.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Nogapendekin alfa inbakicept, hAd5-HPV vaccine, nab-paclitaxel, cisplatin, and de-intensified radiation
What this could lead to
If successful, this approach could offer a more effective and less toxic treatment option for people with HPV-positive oropharyngeal cancer, potentially reducing the need for high-dose radiation.
What could go wrong
This is a Phase 2 trial, so the treatment is still experimental. It may not prove more effective than standard care, and there are risks of side effects from the drugs and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.